Focused on Proving Solutions for Significant Unmet Needs

Our lead product candidate, IMO-2125, has demonstrated activity in a large array of pre-clinical models and is now demonstrating proof of concept in patients through both clinical and translational outcomes in PD-1 refractory melanoma patients.

Our Pipeline

Mechanism Indication Commercial Rights Discovery Phase 1 Phase 2 Pivotal
TLR9 Agonist IMO-2125 Refractory PD-1 Metastatic Melanoma / CPI Comb. Phase 1
IMO-2125 Monotherapy Additional Tumor Types Discovery
IMO-2125 Combo Additional Tumor Types – CPI Comb. Discovery
TLR 7,8,9 Antagonist IMO-8400 Dermatomyositis Phase 2
3GA - Undisclosed Target Undisclosed Rare Liver Condition Discovery
3GA- NLRP3 3GA Undisclosed Indication Discovery
3GA- DUX4 3GA Undisclosed Indication Discovery
3GA 3GA Renal Diseases Discovery
TLR 7,8,9 Antagonist IMO-9200 Autoimmune Diseases Phase 1
Partnering Opportunities – Idera-Sponsored Clinical Development Suspended
TLR 7,8,9 Antagonist IMO-8400 B-Cell Lymphoma Phase 1
TLR 7,8,9 Antagonist
3GA - Undisclosed Target
TLR 7,8,9 Antagonist
Partnering Opportunities – Idera-Sponsored Clinical Development Suspended
TLR 7,8,9 Antagonist

Intratumoral IMO-2125 for Metastatic Melanoma

We are conducting the first of several clinical trials with intratumoral delivery of our TLR9 agonist, IMO-2125, in combination with checkpoint inhibitors—the currently approved treatment for several solid tumor types. Through our strategic research alliance with MD Anderson Cancer Center, our first study is being conducted in patients with metastatic melanoma using the combination of IMO-2125 with an Ipilimumab (anti-CTLA4 antibody). We are also in the planning stages of additional studies in other tumor types and with other checkpoint inhibitors.

IMO-8400 for Rare Diseases

Idera is also advancing the development of IMO-8400 in a rare disease with high unmet clinical need where over-activation of TLRs has been implicated in the disease pathogenesis. We have prioritized near-term development in dermatomyositis, an inflammatory muscle disease with skin involvement.  We are currently enrolling in a multi-national, multi-center, double-blind placebo-controlled Phase 2 clinical trial with completion of enrollment expected in the second half of 2017 and data available in the first half of 2018.

Third Generation Antisense (3GA) Technology Platform

Based on our leadership and scientific expertise in nucleic acid therapeutics, Idera has developed a third-generation antisense platform using gene silencing oligonucleotides (GSOs). This novel technology has been rationally designed to overcome limitations of current antisense platforms, and we have differentiated GSOs from other antisense approaches in pre-clinical models. To date we have generated 22 unique compounds for specific gene targets across a large array of disease indications, which enables an engine for development growth for our own internal aspirations as well as a pipeline of opportunities for partnerships.  We have selected an undisclosed liver target as our first clinical development focus and are expecting to enter the clinic in the first quarter of 2018.  In parallel we also have a licensing collaboration with GSK for an undisclosed renal target, with an expected goal of clinical candidate selection in the first quarter of 2018.

  • Clinical Programs

    Read about our ongoing and planned clinical trials for treating B-cell lymphoma cancers and rare diseases such as Waldenström’s macroglobulinemia and dermatomyositis.